SynAct Pharma AB (SYNACT.ST)
SEK 9.69
(0.36%)
SEK 9.69
(0.36%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -61.75 Million SEK | 41.84% |
| 2022 | -106.18 Million SEK | -407.85% |
| 2021 | -20.9 Million SEK | -43.72% |
| 2020 | -14.54 Million SEK | -309.19% |
| 2019 | -3.55 Million SEK | 50.05% |
| 2018 | -7.11 Million SEK | 30.26% |
| 2017 | -10.2 Million SEK | 61.58% |
| 2016 | -26.56 Million SEK | -63151.44% |
| 2015 | -42 Thousand SEK | 83.4% |
| 2014 | -253 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -61.36 Million SEK | -20.19% |
| 2024 Q3 | -37.99 Million SEK | 39.6% |
| 2024 Q1 | -51.05 Million SEK | 17.33% |
| 2023 FY | -61.75 Million SEK | 41.84% |
| 2023 Q4 | -61.75 Million SEK | -120.01% |
| 2023 Q2 | -43.44 Million SEK | 43.11% |
| 2023 Q1 | -76.37 Million SEK | 28.07% |
| 2023 Q3 | -28.07 Million SEK | 35.39% |
| 2022 Q3 | -52.63 Million SEK | 44.18% |
| 2022 Q4 | -106.18 Million SEK | -101.74% |
| 2022 FY | -106.18 Million SEK | -407.85% |
| 2022 Q1 | -3.92 Million SEK | 81.22% |
| 2022 Q2 | -94.29 Million SEK | -2301.78% |
| 2021 Q3 | -44.4 Million SEK | 28.99% |
| 2021 Q2 | -62.53 Million SEK | 20.73% |
| 2021 Q1 | -78.88 Million SEK | -442.23% |
| 2021 FY | -20.9 Million SEK | -43.72% |
| 2021 Q4 | -20.9 Million SEK | 52.91% |
| 2020 Q1 | -8.15 Million SEK | -129.39% |
| 2020 FY | -14.54 Million SEK | -309.19% |
| 2020 Q4 | -14.54 Million SEK | 44.48% |
| 2020 Q3 | -26.2 Million SEK | -516.86% |
| 2020 Q2 | -4.24 Million SEK | 47.92% |
| 2019 Q4 | -3.55 Million SEK | -280.87% |
| 2019 Q3 | -933.46 Thousand SEK | 77.49% |
| 2019 Q1 | -2.74 Million SEK | 61.49% |
| 2019 FY | -3.55 Million SEK | 50.05% |
| 2019 Q2 | -4.14 Million SEK | -51.31% |
| 2018 Q2 | -19.78 Million SEK | -194.55% |
| 2018 FY | -7.11 Million SEK | 30.26% |
| 2018 Q4 | -7.11 Million SEK | 44.71% |
| 2018 Q1 | -6.71 Million SEK | 34.2% |
| 2018 Q3 | -12.87 Million SEK | 34.92% |
| 2017 Q4 | -10.2 Million SEK | 27.36% |
| 2017 Q3 | -14.04 Million SEK | 22.12% |
| 2017 FY | -10.2 Million SEK | 61.58% |
| 2017 Q1 | -21.09 Million SEK | 20.61% |
| 2017 Q2 | -18.04 Million SEK | 14.46% |
| 2016 Q2 | -8.34 Million SEK | 0.0% |
| 2016 Q3 | -34 Million SEK | -307.71% |
| 2016 Q4 | -26.56 Million SEK | 21.88% |
| 2016 FY | -26.56 Million SEK | -63151.44% |
| 2015 FY | -42 Thousand SEK | 83.4% |
| 2014 FY | -253 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -23.464% |
| Ziccum AB (publ) | -2.13 Million SEK | -2789.939% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -224.019% |
| BioArctic AB (publ) | -606.58 Million SEK | 89.819% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -23.679% |
| Mendus AB (publ) | -96.29 Million SEK | 35.865% |
| Genovis AB (publ.) | -43.94 Million SEK | -40.548% |
| Intervacc AB (publ) | -88.16 Million SEK | 29.948% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 401.112% |
| Active Biotech AB (publ) | -33.2 Million SEK | -86.018% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 216.036% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -56.818% |
| Aptahem AB (publ) | 2.9 Million SEK | 2223.259% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 81.489% |
| Kancera AB (publ) | -45.69 Million SEK | -35.162% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 81.232% |
| Fluicell AB (publ) | -2.76 Million SEK | -2135.179% |
| Saniona AB (publ) | 40.44 Million SEK | 252.689% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -93.435% |
| Biovica International AB (publ) | -58.73 Million SEK | -5.143% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -36.581% |
| AcouSort AB (publ) | -23.98 Million SEK | -157.475% |
| Xintela AB (publ) | -7.8 Million SEK | -690.857% |
| Abliva AB (publ) | -57.24 Million SEK | -7.893% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 68.28% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 24.87% |
| OncoZenge AB (publ) | -12.62 Million SEK | -389.095% |
| Amniotics AB (publ) | -5.63 Million SEK | -996.555% |
| 2cureX AB (publ) | -13.4 Million SEK | -360.777% |
| CombiGene AB (publ) | -101.44 Million SEK | 39.119% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2757.844% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1243.667% |
| Camurus AB (publ) | -1.16 Billion SEK | 94.7% |
| Corline Biomedical AB | -17.01 Million SEK | -263.026% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 26.253% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 55.296% |
| I-Tech AB | -83.26 Million SEK | 25.827% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 145.846% |
| Cyxone AB (publ) | -16.67 Million SEK | -270.474% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -10.507% |
| Biosergen AB | -1.88 Million SEK | -3179.766% |
| Cantargia AB (publ) | -139.74 Million SEK | 55.807% |
| NextCell Pharma AB | -46.79 Million SEK | -31.988% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 52.309% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -110.183% |
| Nanologica AB (publ) | -9.38 Million SEK | -557.84% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -188.387% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -366.832% |
| LIDDS AB (publ) | -13.51 Million SEK | -357.06% |
| Lipum AB (publ) | -8.46 Million SEK | -629.569% |
| BioInvent International AB (publ) | -236.3 Million SEK | 73.865% |
| Alzinova AB (publ) | -21.22 Million SEK | -190.954% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 7.714% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1092.028% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 26.251% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -6591.008% |
| Simris Alg AB (publ) | 85.07 Million SEK | 172.592% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 24.764% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 137.186% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -197.013% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1977.995% |